我们回顾了有关环状 RNA (circRNA) 在临床前胰腺癌相关体内模型中有效的文献。已鉴定的 circRNA 靶向化疗耐药机制 (n=5)、分泌蛋白和跨膜受体 (n=15)、转录因子 (n=9)、信号传导成分 - (n=11)、泛素化 - (n=2)、自噬系统（n=2）和其他（n=9）。除了确定治疗干预的靶点外，circRNA 也是治疗胰腺癌的潜在新实体。上调的 circRNA 可以通过反义寡核苷酸 (ASO)、小干扰 RNA (siRNA)、短发夹 RNA (shRNA) 或基于成簇规则间隔短回文重复序列-CRISPR 相关蛋白 (CRISPR-CAS) 的干预来抑制。下调的 circRNA 的功能可以通过使用质粒或基于病毒的载体系统的替代疗法来重建。对目标验证实验和相应药物的改进递送系统的开发进行了检查。版权所有 © 2024，国际抗癌研究所（George J. Delinasios 博士），保留所有权利。

We have reviewed the literature for circular RNAs (circRNAs) with efficacy in preclinical pancreatic-cancer related in vivo models. The identified circRNAs target chemoresistance mechanisms (n=5), secreted proteins and transmembrane receptors (n=15), transcription factors (n=9), components of the signaling- (n=11), ubiquitination- (n=2), autophagy-system (n=2), and others (n=9). In addition to identifying targets for therapeutic intervention, circRNAs are potential new entities for treatment of pancreatic cancer. Up-regulated circRNAs can be inhibited by antisense oligonucleotides (ASO), small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs) or clustered regularly interspaced short-palindromic repeats-CRISPR associated protein (CRISPR-CAS)-based intervention. The function of down-regulated circRNAs can be reconstituted by replacement therapy using plasmids or virus-based vector systems. Target validation experiments and the development of improved delivery systems for corresponding agents were examined.Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.